1. Brouwer KLR, Dukes GE, Powell JR. Influence of liver function on drug disposition. In. Evans WE, Schentag JJ, Jusko WJ (eds.). Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring 3rd ed. Vancouver, WA. Applied Therapeutics, Inc., 1992, 6-1 to 6-59.

2. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet. 1999,37(5):399-431.

3. Boggs J, Waterhouse E, DeLorenzo RJ. The use of antiepileptic medications in renal and liver disease. In. Wyllie E (ed). The Treatment of Epilepsy: principles and Practice, 2nd ed. Baltimore, Williams & Wilkins, 1996, 753-762.

4. Rowland M, Tozer. Absorption. Clinical Pharmacokinetics: Concepts and Applications 2nd ed. Philadelphia, Lea & Febiger, 1989, 113-130.

5. Anderson GD, Levy RH. Phenobarbital: Chemistry and Biotransformation. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:371- 377.

6. Dodson WE, Rust Jr RS. Phenobarbital: Absorption, distribution, and excretion. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:379- 387.

7. Alvin J, McHorse T, Hoyumpa A, Bush MT, Schenker S. The effect of liver disease in man on the disposition of phenobarbital. J Pharmacol Exp Ther. 1975;192:224-235.

8. Browne TR, LeDuc B. Phenytoin: Chemistry and Biotransformation. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:283-300.

9. Treiman DM, Woodbury DM. Phenytoin: Absorption, distribution, and excretion. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:301-314.

10. Tozer TN, Winter ME. In, Evans WE, Schentag JJ, Jusko WJ (eds.). Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring 3rd ed. Vancouver, WA. Applied Therapeutics, Inc., 1992, 25-1 to 25-44.

11. Kutt H, Winters W, Scherman R, McDowell R. Diphenylhydantoin and phenobarbital toxicity. The role of liver disease. Arch Neurol. 1964;11:649-656.

12. Hooper WD, Bochner F, Endre MJ, Tyrer JH. Plasma protein binding of diphenylhydantoin. Effects of sex, hormones, renal and hepatic disease. Clin Pharmacol Ther. 1974;15:276-282.

13. Olsen GD, Bennett WM, Porter GA. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther. 1975;17:677-684.

14. Reidenberg MN, Affrime M. Influence of disease on binding of drugs to plasma proteins. Ann NY Acad Sci. 1973;226:115-126.

15. Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clin Pharmacol Ther. 1975;17:685-691.

16. Lunde PKM, Rane A, Yaffe SJ, Lund L. Sjoqvist F. Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther. 1970;11:846-855.

17. Rane A, Lunde PKM, Jalling B, Yaffe S, Sjoqvist F. Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. J Pediatr. 1971;78:877-882.

18. Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kugler AR, Alldredge BK. Pharmacokinetics of fosphenytoin in patients with hepatic and renal disease. Epilepsia. 1999;40(6):777-82.

19. Garnett WR. Ethosuximide. In, Taylor WJ, Caviness MHD (eds). A Textbook for the Clinical Application of Therapeutic Drug Monitoring. Abbott Laboratories, Diagnostics Division, Irving, 1986, 225-235.

20. Pisani F, Bialer M. Ethosuximide: Chemistry and Biotransformation. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:655-658.

21. Mialer M, Xiaodong S, Perucca E. Ethosuximide: Absorption, Distribution, and Excretion. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:659-665.

22. Faigle JW, Feldmann KF. Carbamazepine: Chemistry and Biotransformation. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:499-513.

23. Morselli PL. Carbamazepine: Absorption, Distribution, and Excretion. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:515-528.

24. Hooper WD, Dubetz DK, Bochner F, Cotter LM, et al. Plasma protein binding of carbamazepine. Clin Pharmacol Ther. 1975;17:433-440.

25. Wilding IR, Davis SS, Hardy JG, et al. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. Br J Clin Pharmacol. 1991;32:573-9.

26. Baillie TA, Sheffels PR. Valproic Acid: Chemistry and Biotransformation. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:589 - 604.

27. Levy RH, Shen DD. Valproic Acid: Absorption, Distribution, and Excretion. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:605-619.

28. Klotz U, Rapp T, Mueller WA. Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol. 1978;13:55-60.

29. Siemes H, Nau H, Schulze K, et al. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 1993;34:332-346.

30. Kucharczk N. Felbamate: Chemistry and Biotransformation. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:799- 806.

31. Perhach JL, Shumaker RC. Felbamate: Absorption, Distribution, and Excretion. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:807-812.

32. McLean MJ. Gabapentin: Chemistry, Absorption, Distribution, and Excretion. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:843 - 849.

33. Garnett WR. Lamotrigine: Pharmacokinetics. J Child Neurol. 1997;12(Suppl.1):S10-S15.

34. Dickins M, Sawyer DA, Morley TJ, Parsons DN. Lamotrigine: Chemistry and Biotransformation. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:871-75.

35. Parsons DN, Dickins M, Morley TJ. Lamotrigine: Absorption, Distribution, and Excretion. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:877-881.

36. Posner J, Cohen AF, Land G, Peck AW. The pharmacokinetics of lamotrigine (BW 430C) in health subjects with unconjugated hyperbilirubinemia (Gilbert’s syndrome). Br J Clin Pharmacol. 1989:28:117-120.

37. Garnett WR. Clinical pharmacology of topiramate: A review. Epilepsia. 2000;41(Suppl. 1):S61-S65.

38. Doose DR, Walker SA, Venkataramanan R, Rabinovitz M, Lever J. Topiramate pharmacokinetics in subjects with liver impairment. J Pharm Res. 1994;11(Suppl):S446.

39. Gustavson LE, Mengesl HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-11.

40. Lau AH, Gustavson LE, Sperelakis R, Lam NP, El-Shourbagy T, Qian JX, Layden T. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia. 1997;38(4):445-451.

41. Patsalow PN. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics. Pharmacol Ther. 2000;85(2):77-85.

42. Tecoma ES. Oxcarbazepine. Epilepsia. 1999;40(Suppl 5):S37-S46.

43. Dam M, Ostergaard LH. Oxcarbazepine. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:987-995.

44. Leppik IE. Zonisamide. Epilepsia. 1999;40(Suppl 5):S23-S29.

45. Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol. 1998;38(2):166-71.

46. Seino M, Naruto S, Ito T, Miyazaki H. Zonisamide. In Levy RH, Mattson RH, Meldrum BS (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995:1011-1023.

47. Krauss G, Crone N. Non-CNS side effects of antiepileptic drugs. Medscape (http://www.medscape.com/viewprogram/308), February 2000.

48. Camfield C, Camfield P, Smith E, Tibbles JA. Asymptomatic children with epilepsy: little benefit from screening for anticonvulsant-induced liver, blood, or renal damage. Neurology 1986;36:838-841.

49. Haidukewych D, John G. Chronic valproic acid and coantiepileptic drug therapy and incidence of increases in serum liver enzymes. Ther Drug Monit. 1986;8:407–410.

50. Kugoh T, Yamamoto M, Hosokawa K. Blood ammonia level during valproic acid therapy. Jpn J Psychiatry Neurol. 1986;40:663–668.

51. Zaccara G, Paganini M, Campostrini R, et al. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia. Ther Drug Monit. 1985;7:185–190.

52. Schlienger RG, Shear NH, Antiepileptic drug hypersensitivity syndrome. Epilepsia. 1998;39:S3–S7.

53. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management Drug Safety. 1999;21:489–501.

54. Asconape JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia. 1993;34:177–183.

55. Binek J, Hany A, Heer M. Valproic-acid–induced pancreatitis. Case report and review of the literature. J Clin Gastroenterol. 1991;13:690–693.

Adapted from: Garnett WR. Gastrointestinal and hepatic disease. In: Ettinger AB and Devinsky O, eds. Managing epilepsy and co-existing disorders. Boston: Butterworth-Heinemann; 2002;63-74. 
With permission from Elsevier (www.elsevier.com).

I<